<DOC>
	<DOCNO>NCT01163916</DOCNO>
	<brief_summary>The primary objective post-marketing observational study obtain data characteristic ( patient age/gender ; disease type , severity duration ; disease specific treatment history ; current concomitant medication ; relevant medical history ) patient prescribe adalimumab ( Humira® ) rheumatoid arthritis ( RA ) , ankylose spondylitis ( AS ) psoriatic arthritis ( PsA ) part routine clinical care Russia .</brief_summary>
	<brief_title>Study Characterize Demographics , Compliance , Tolerability Safety Patients With Rheumatoid Arthritis , Psoriatic Arthritis Ankylosing Spondylitis Prescribed Adalimumab ( Humira® ) Part Routine Clinical Care</brief_title>
	<detailed_description>This non-interventional , observational study adalimumab prescribe usual manner accordance term local marketing authorization regard dose , population indication . No data currently exist characterize patient type adalimumab administration within Russian population . Further , important characterize compliance , acceptability patient self-injection , tolerability safety profile therapy option routine clinical care . The total follow-up participant plan 12 month , approximately 6 follow-up visit occur average interval 2-3 month . However , since observational study , follow-up perform accord routine clinical practice ; 127 participant follow-up period consist 12 month maximum observation period last 18.2 month . Follow-up visit designate sequential visit number ( Visit 1-6 ) , regardless time point occur .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients adalimumab therapy indicate accord product label meet follow criterion : Patients newly prescribe adalimumab therapy ( prior history treatment adalimumab ) include patient infliximab treatment history . Patients complete Abbott sponsor interventional trial continue treatment commercial adalimumab thereafter . The following patient include study : Patients treat treated drug risk interaction adalimumab . Hypersensitivity adalimumab Pregnancy Lactation Age 18 Infectious disease include tuberculosis Patients currently participate another clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Ankylosing Spondylitis</keyword>
</DOC>